Scarica l'app Stockscreener
0.90
8.62%
0.0714
Dopo l'orario di chiusura:
.88
-0.02
-2.22%
Precedente Chiudi:
$0.8286
Aprire:
$1.02
Volume 24 ore:
49.05M
Relative Volume:
6.95
Capitalizzazione di mercato:
$3.30M
Reddito:
-
Utile/perdita netta:
$-11.38M
Rapporto P/E:
-0.0325
EPS:
-27.73
Flusso di cassa netto:
$-12.72M
1 W Prestazione:
+33.33%
1M Prestazione:
+50.00%
6M Prestazione:
+296.65%
1 anno Prestazione:
-75.74%
Intervallo 1D:
$0.6493
$1.06
Intervallo di 1 settimana:
$0.63
$1.06
Portata 52W:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Nome
Windtree Therapeutics Inc
Settore
Industria
Telefono
(215) 488-9300
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Confronta WINT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.90 | 2.88M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.40 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.77 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-26 | Iniziato | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
Windtree to raise $200M to launch a BNB treasury strategy - TheStreet
Windtree to Invest $200M in BNB treasury, First NASDAQ Firm to Do So - The Crypto Times
Windtree Therapeutics to Raise $60 Million via BNB Treasury Strategy - AInvest
Windtree Therapeutics Secures $200 Million for BNB Crypto Treasury Strategy - AInvest
Windtree Therapeutics enters $60 million deal to launch BNB crypto strategy - Investing.com
Windtree Therapeutics, Inc. Announces $60 Million Securities Purchase Agreement to Launch BNB Crypto Treasury Strategy - Quiver Quantitative
Windtree Therapeutics enters $60 million BNB crypto treasury deal By Investing.com - Investing.com South Africa
Windtree Therapeutics enters $60 million BNB crypto treasury deal - Investing.com
Windtree Makes Historic Move: Secures $60M to Become First NASDAQ-Listed BNB Crypto Player - Stock Titan
Why Windtree Therapeutics Inc. stock attracts strong analyst attentionSteady Profit Stock Forecasts - Newser
What makes Windtree Therapeutics Inc. stock price move sharply200 Percent Profit Outlook - Newser
Windtree Therapeutics (WINT) Soars 13.92% on U.S. Patent Issuance - AInvest
Windtree Therapeutics Explodes 27%—What’s Fueling the Surge? - AInvest
Why WINT Stock is Surging? - StocksToTrade
Windtree Therapeutics Soars 76.71% on Patent Win - AInvest
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Windtree Therapeutics (NASDAQ:WINT) Trading Down 14.1% – Here’s What Happened - Defense World
Windtree Therapeutics Secures U.S. Patent for Istaroxime Heart Failure Treatment - MSN
Windtree Therapeutics Plunges 12.06% Amid High Short Interest - AInvest
Windtree Therapeutics Soars 25.97% on Patent Win - AInvest
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment - MSN
Windtree’s Stock Upsurge: Is Innovation the Key? - StocksToTrade
Windtree Therapeutics Issues Convertible Promissory Notes - TipRanks
Windtree Therapeutics receives U.S. patent for istaroxime heart failure drug - Investing.com
Windtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - Nasdaq
Windtree Therapeutics receives U.S. patent for istaroxime heart failure drug By Investing.com - Investing.com India
1.3M Patient Market: Windtree Secures Critical Patent for Revolutionary Heart Failure Treatment Until 2039 - Stock Titan
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis - The Manila Times
Windtree's Breakthrough Cardiogenic Shock Drug Hits Critical Trial Milestone: What's Next for istaroxime? - Stock Titan
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel - The Manila Times
Windtree Advances Lower Cost Manufacturing Of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel - TradingView
Windtree Therapeutics CFO Resignation and Leadership Shift - TipRanks
Windtree Therapeutics Receives Nasdaq Deficiency Letter - MSN
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MSN
Warrington’s Windtree Therapeutics Acquires Waste Management Company - MSN
Windtree Therapeutics (WINT) Publishes Promising Phase 2 Study R - GuruFocus
Ratios Revealed: Decoding Windtree Therapeutics Inc (WINT)’s Financial Health - DWinneX
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | WINT Stock News - GuruFocus
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study - Yahoo Finance
Breakthrough Heart Treatment: Istaroxime Phase 2 Trial Hits All Endpoints for $1.25B Cardiogenic Shock Market - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May - Defense World
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Titan Environmental to be acquired by Windtree Therapeutics - Investing.com Nigeria
Titan Environmental to be acquired by Windtree Therapeutics By Investing.com - Investing.com South Africa
Windtree Therapeutics Stock Is Volatile This Week: What's Going On? - Benzinga
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics receives $7M offer for oncology platform By Investing.com - Investing.com South Africa
Windtree Therapeutics Raises $3.9M Through Note Agreements - TipRanks
Windtree Therapeutics (WINT) Receives Offer for Oncology Platfor - GuruFocus
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate - The Manila Times
Windtree Therapeutics (WINT) Receives Offer for Oncology Platform | WINT Stock News - GuruFocus
Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.38%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):